Table 1 Risk factor associate with PZA resistance among 133 MDRa isolates
Characteristics | No. (%) of isolates (n = 133) | No. (%) of isolates | OR (95% CI) | P value | |
|---|---|---|---|---|---|
PZAR (n = 83) | PZAS (n = 50) | ||||
Sex | |||||
Male | 80 (60.2) | 47 (56.6) | 33 (66.0) | 0.67 (0.33–1.39) | 0.29 |
Female | 53 (39.8) | 36 (43.4) | 17 (34.0) | 1.0 (Ref.) | – |
Age group | |||||
< 30 | 31 (23.3) | 18 (21.7) | 13 (26.0) | 1.0 (Ref.) | – |
30–59 | 80 (60.2) | 55 (66.3) | 25 (50.0) | 1.59 (0.68–3.74) | 0.29 |
≥ 60 | 22 (16.5) | 10 (12.0) | 12 (24.0) | 0.60 (0.20–1.81) | 0.36 |
Treatment history | |||||
New case | 49 (36.8) | 22 (26.5) | 27 (54.0) | 1.00 (Ref.) | – |
Re-treated | 84 (63.2) | 61 (73.5) | 23 (46.0) | 3.26 (1.55–6.82) | <0.01 |
Resistance to: | |||||
SM | 97 (72.9) | 69 (83.1) | 28 (56.0) | 3.87 (1.74–8.63) | <0.01 |
EMB | 40 (30.1) | 26 (31.3) | 14 (28.0) | 1.17 (0.54–2.54) | 0.69 |
OFLX | 52 (39.1) | 43 (51.8) | 9 (18.0) | 4.89 (2.11–11.35) | <0.01 |
KAN | 20 (15.0) | 19 (22.9) | 1 (2.0) | 14.58 (1.88–112.44) | <0.01 |
AMK | 16 (12.0) | 15 (18.1) | 1 (2.0) | 10.81 (1.38–84.58) | 0.01 |
CAP | 11 (8.3) | 10 (12.0) | 1 (2.0) | 6.71 (0.83–54.12) | 0.05 |
PAS | 15 (11.3) | 13 (15.7) | 2 (4.0) | 4.46 (0.96–20.65) | 0.04 |
Pre-XDRb | 38 (28.6) | 30 (36.1) | 8 (16.0) | 2.97 (1.23–7.16) | 0.02 |
XDRc | 17 (12.8) | 16 (19.3) | 1 (2.0) | 11.70 (1.50–91.22) | <0.01 |